(Q37565259)

21 August 2017

1 reference

title

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes (English)

1 reference

21 August 2017

1 reference

Troy Dillard

1

1 reference

21 August 2017

Chris G Yedinak

series ordinal

2

1 reference

21 August 2017

Joshi Alumkal

series ordinal

3

1 reference

21 August 2017

Maria Fleseriu

series ordinal

4

1 reference

21 August 2017

publication date

29 July 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

13

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

29-38

1 reference

Phase I/II study of ipilimumab for patients with metastatic melanoma

21 August 2017

cites work

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Lymphocytic hypophysitis: disease spectrum and approach to diagnosis and therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Lymphocytic hypophysitis: case report

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Infundibulohypophysitis in a man presenting with diabetes insipidus and cavernous sinus involvement

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Lymphocytic hypophysitis. A review of 145 cases.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Pituitary autoimmunity: 30 years later.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Fatal inflammatory hypophysitis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

https://pubmed.ncbi.nlm.nih.gov/19639414

1 reference

12 December 2020

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Primary hypophysitis: a single-center experience in 16 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Lymphocytic infundibulo-neurohypophysitis and infundibulo-panhypophysitis regarded as lymphocytic hypophysitis variant

1 reference

https://pubmed.ncbi.nlm.nih.gov/19639414

12 December 2020

Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2005.23.16_SUPPL.7525

A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.3035

Identifiers

DOI

10.1007/S11102-009-0193-Z

1 reference

21 August 2017

1 reference